Overweight and Obesity-Induced Oxidative Stress in Children

Objective To investigate whether overweight and obesity might cause oxidative stress and potential oxidative damage in overweight and obese children, and to explore its possible mechanism. Methods Eighty-five overweight and obese children （OOC）, and eighty-five age-matched healthy children （HC） were recruited in this case-control study. The present study analyzed spectrophotometrically vitamin C （VC）, vitamin E （VE）, and β-carotene （β-CAR） in plasma, as well as the activities of superoxide dismutase （SOD）, catalase （CAT）, and the level of malondialdehyde （MDA） in erythrocytes. Results Compared with those of VC, VE, β-CAR, SOD, CAT and MDA in the HC group, the average values of VC, VE, β-CAR, SOD, and CAT in the OOC group were significantly decreased （P〈0.001）, while the average value of MDA in the OOC group was significantly increased （P〈0.001）. The regression analysis demonstrated that VC, VE, β-CAR, SOD, and CAT were negatively correlated （P〈0.05-0.01）, and MDA was positively correlated with BMI （P〈0.05）. Fitting to the model of multiple stepwise regression of BMI on VC, VE, β-CAR, SOD, CAT, and MDA in 85 OOC was Y = 27.0041 ＋ 0,2541MDA - 2.1448β-CAR -- 0.0090CAr, where F = 43.8088, P〈0.001, r = 0.7866, r^2= 0.6187, adjusted r^2= 0.6046. The findings from the reliability analysis for VC, VE, β-CAR, SOD, CAT, and MDA used to reflect increased oxidative stress and potential oxidative damage in the OOC showed that the reliability coefficients （alpha, 6 items） = 0.7231, P〈0.0001, and that the standardized item alpha = 0.9207, P〈0.0001, Conclusion The present study suggests that there exists an increased oxidative stress in overweight and obese children.

Clinical Study of Pai-Neng-Da Capsule(派能达胶囊) in the Treatment of Chronic Aplastic Anemia

Objective：To evaluate the efficacy and safety of Pai-Neng-Da Capsule（派能达胶囊t panaxadiol saponins component,PND）,a new Chinese patent medicine,on patients with chronic aplastic anemia（CAA）and to explore the optimal therapeutic regimen for CAA.Method：A total of 36 patients with CAA were enrolled and divided into three groups：the AP group（20 cases,andriol 120 mg/day ＋ PND 240 mg/day）,the ACP group（13 cases,andriol 120 mg/day ＋ cyclosporine 3-6 mg·kd（-1）·day（-1） ＋ PND 240 mg/day）,and the PND group（3cases,PND 240 mg/day）.All patients were treated and followed up for 6 months.Peripheral blood counts,renal and hepatic function and Chinese medical（CM） symptoms of patients were assessed and all indices were gathered at the beginning and end of the study.Result：In the AP group,no significant hematologic difference was observed at the end of 6-month treatment comparing with the beginning.In the ACP group,the blood counts were maintained at the same level after the 6-month treatment.In the PND group,trilineage hematologic improvement was displayed at the end of 6-month treatment comparing with the beginning.No significant difference was showed in renal and hepatic function in all patients.All patients＇ clinical symptom improved according to CM symptom score.The effective rates were 95%,73%and 100%,respectively.Conclusion：PND improved the efficacy and decreased side effects by cutting down the dosage of andriol,and it could also improve patients＇ clinical symptom and quality of life.PND were effective and safe in the treatment of CAA,it could be used alone or in combination with pharmacological agents such as andriol and cyclosporine.